Last reviewed · How we verify
TICARCILLIN
Ticarcillin is a Penicillin-class Antibacterial small molecule originally developed by, currently owned by. It was FDA approved in 1976 for various bacterial infections, including lung abscess, aspiration pneumonia, and urinary tract infections. Ticarcillin is off-patent and has a generic manufacturer. Its half-life is 1.0 hours, but it has 0% bioavailability. It is used to treat a range of bacterial infections caused by various pathogens.
At a glance
| Generic name | TICARCILLIN |
|---|---|
| Drug class | Penicillin-class Antibacterial |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1976 |
Approved indications
- Abscess of lung
- Aspiration pneumonia
- Bacterial infection due to Klebsiella pneumoniae
- Bacterial infection due to Serratia
- Bacterial pneumonia
- Bacterial septicemia
- Bacterial urinary infection
- Bacteroides Endometritis
- Bacteroides Peritonitis
- Citrobacter Urinary Tract Infection
- Complicated Genitourinary Tract Infection
- Complicated Urinary Tract Infections
- E. Coli Endometritis
- E. Coli Peritonitis
- Empyema of pleura
- Enterobacter Endometritis
- Enterobacter Pneumonia
- Escherichia coli urinary tract infection
- Genitourinary Tract Infections
- Haemophilus influenzae pneumonia
Common side effects
Drug interactions
- tobramycin
Key clinical trials
- Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio) (PHASE1)
- The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial (NA)
- Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD (PHASE2,PHASE3)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis (PHASE4)
- An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038) (PHASE2)
- Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients (PHASE2)
- WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TICARCILLIN CI brief — competitive landscape report
- TICARCILLIN updates RSS · CI watch RSS